$23.90 0.25 (+1.06%)
11/20/2009 4:00 PM

Acorda Therapeutics, Inc. (ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Current Price $23.90 Mkt Cap $911.07M
Open $23.48 P/E Ratio 0.00
Prev. Close $23.65 Div. (Yield) N/A (N/A)
Daily Range $23.13 - $24.09 Volume 619,604
52-Wk Range $14.42 - $29.27 Avg. Daily Vol. 1,895,000

ACOR News and Commentary

Caps

How do you think ACOR will perform vs the S&P 500?

Add Stock to Watchlist

All Members

168 Outperform
103 Underperform
 

All-Star Members

41 Outperform
48 Underperform
 

Wall Street

12 Outperform
3 Underperform
 

Top ACOR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.51)
Submitted March 31, 2009

I'm green thumbing Acorda as one of those win-win situations where I don't know the bottom. Fampridine obviously has too much behind it to be summarily dismissed by the FDA, so I'm counting on the rejection of the NDA submission to be a simple… More

0 Comments | Reply | Report this Post

evillate (< 20)
Submitted June 02, 2008

Big jump is too big. I'll watch it come down

0 Comments | Reply | Report this Post
ACOR VS S&P 500 (SPY)

Fools bullish on ACOR are also bullish on:

Fools bearish on ACOR are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about ACOR.

Recs

0
Member Avatar rogerisi (55.79) Submitted: 11/18/2009 9:52:33 AM : Outperform Start Price: $23.53 ACOR Score: +2.90

poor management, this one's going no where.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar power1234 (99.80) Submitted: 11/13/2009 2:50:10 PM : Outperform Start Price: $23.42 ACOR Score: +1.92

screened

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar joseviii (53.38) Submitted: 11/3/2009 11:06:32 AM : Outperform Start Price: $21.81 ACOR Score: +4.47

Specializing in Neurological function repair and improvement. They have a drug that helps MS patients walk that should get FDA approval in January. I can sense that they are on the brink of other break throughs. Should get a boost when health care reform finally passes.

Report this Post 1 Comment | Reply | Permalink
View All 35 Pitches »

Leaderboard

Find the members with the highest scoring picks in ACOR.

Score Leader

Jeffreyw

Jeffreyw (97.83) Score: +231.14

Risky and volatile, there is much promise in the research and great demand in this area for successful therapies to treat spinal injuries, MS and central nervous system disorders.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
kaiseras 57.94 10/2/2006 Outperform 3M $8.88 +169.14% -13.01% +182.15
ignorant1 67.44 10/2/2006 Outperform 1Y $8.88 +169.14% -13.01% +182.15
EddieBhai 24.44 9/29/2006 Outperform 1Y $9.27 +157.82% -13.18% +171.00
fool1e7 56.91 9/29/2006 Outperform 3W $9.60 +148.96% -13.23% +162.19
pkurkjian 84.42 9/27/2006 Outperform 3W $10.30 +132.04% -12.94% +144.98
papabearof5 < 20 10/4/2006 Outperform 3W $11.00 +117.27% -13.61% +130.89
stockquoter < 20 9/26/2006 Outperform 1Y $11.09 +115.51% -12.84% +128.35
hamzavi < 20 10/5/2006 Outperform 3M $12.60 +89.68% -14.01% +103.69
benariel < 20 10/6/2006 Outperform NS $13.19 +81.20% -13.88% +95.08
wmatin 62.69 10/9/2006 Outperform 3W $14.92 +60.19% -13.87% +74.06
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackMerriman < 20 10/15/2009 Outperform NS $25.07 -4.67% +0.60% -5.26
TrackRodmanRen < 20 10/12/2009 Underperform NS $17.72 +34.88% +1.44% -33.43
TrackPiperJaff 78.45 8/5/2009 Outperform NS $24.85 -3.82% +9.12% -12.94
TrackLeerinkSwan 83.04 7/2/2009 Outperform NS $24.90 -4.02% +20.66% -24.67
TrackZacks 70.74 4/23/2009 Outperform 3M $21.89 +9.18% +29.52% -20.34 1 Comment
TrackHapoalim 45.06 3/24/2009 Outperform NS $26.70 -10.49% +36.10% -46.59
TrackFTNEquityCa < 20 3/12/2009 Outperform NS $25.25 -5.35% +52.87% -58.21
TrackRBCCapMkts 82.07 11/7/2008 Outperform NS $20.22 +18.20% +20.71% -2.51
TrackRWBaird 81.68 11/3/2008 Outperform NS $21.13 +13.11% +15.89% -2.78
TrackZacks 70.74 6/4/2008 Underperform 3M $30.15 -39.73% -29.35% +10.38 10/8/2008 @ $18.17 1 Comment
TrackIcahn 22.83 9/30/2007 Outperform NS $18.35 +19.67% -3.67% +23.34 12/31/2007 @ $21.96 1 Comment
TrackFortisBank 85.69 6/21/2007 Outperform NS $17.87 +33.74% -23.89% +57.63
TrackBofASec 91.37 6/19/2007 Outperform NS $19.60 +21.94% -24.42% +46.36
TrackDeutscheSec 87.23 4/12/2007 Outperform NS $23.50 +1.70% -19.99% +21.69
TrackFBRCapitalM 73.72 4/11/2007 Outperform NS $21.37 +41.79% -9.07% +50.86 6/23/2008 @ $30.30
TrackMorganJos < 20 2/21/2007 Underperform NS $23.40 +2.14% -20.24% -22.37
TrackJimCramer 36.31 10/12/2006 Underperform 3W $17.12 +39.60% -15.06% -54.67
TrackPiperJaff 78.45 9/29/2006 Outperform NS $9.73 +163.62% -30.73% +194.35 7/1/2009 @ $25.65
TrackBofASec 91.37 9/26/2006 Outperform NS $10.09 +131.91% +9.84% +122.07 2/21/2007 @ $23.40
TrackLazardCapit < 20 9/26/2006 Outperform NS $10.09 +136.87% -12.33% +149.20

Featured Broker Partners